ArticleScientific reports2026
The impact of sex on the efficacy of anti-TNF-α therapy in Crohn's disease patients with different visceral adipose tissue levels.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Sex, location, and visceral adipose tissue (VAT) influence the course of Crohn’s disease (CD). However, the combined impact of these factors has not been consistently or thoroughly considered in anti-tumour necrosis factor-α (anti-TNF-α) therapy. This study aims to investigate how sex, location, and VAT levels affect the efficacy of IFX treatment in CD patients. This retrospective multicenter study included 182 CD patients (120 males and 62 females) who received IFX therapy between January 2014 and January 2024. There was a statistically significant difference in remission rates between male visceral obesity group (M-VATH) and male non-visceral obesity group (M-VATL) at 6 months (p < 0.001) and 12 months (p < 0.001). Similar differences in remission rates were observed between the male colon-uninvolved visceral obesity group and the male colon-uninvolved non-visceral obesity group at 6 months (p < 0.001) and 12 months (p < 0.001). Additionally, serum TNF-α concentrations (p = 0.010)and IFX trough concentrations (p = 0.003) showed significant differences between M-VATH and M-VATL. The VAT area was identified as a predictor of IFX efficacy in male patients, with an area under the receiver operating characteristic curve of 0.813, sensitivity of 73.9%, and specificity of 78.1% (95% CI, 0.730–0.896). Sex and location influence the predictive function of VAT for IFX efficacy. VAT may be an accurate predictor of IFX efficacy in male colon-uninvolved CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.